These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31062695)

  • 21. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.
    Han Y; Xu B; Fu G; Wang X; Xu K; Jin C; Tao L; Li L; Hou Y; Su X; Fang Q; Chen L; Liu H; Wang B; Yuan Z; Gao C; Zhou S; Sun Z; Zhao Y; Guan C; Stone GW;
    JACC Cardiovasc Interv; 2018 Feb; 11(3):260-272. PubMed ID: 29413240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restenosis of Coronary Bioresorbable Vascular Scaffolds.
    Alfonso F; García-Guimaraes M
    Rev Esp Cardiol (Engl Ed); 2017 Jul; 70(7):527-531. PubMed ID: 28285939
    [No Abstract]   [Full Text] [Related]  

  • 24. Serial optical coherence tomography of drug-eluting stent in-stent restenosis treated with the Absorb bioresorbable scaffold: an effective treatment?
    Farooq V; Mamas MA; Fraser DG; El-Omar M; Clarke B; Fath-Ordoubadi F
    EuroIntervention; 2015 Mar; 10(11):e1. PubMed ID: 25798636
    [No Abstract]   [Full Text] [Related]  

  • 25. Successful use of bioresorbable vascular scaffold in in-stent restenosis previously exposed to vascular brachytherapy.
    Wong KL; Fan KY; Jim MH
    Int J Cardiol; 2015 Feb; 181():1-2. PubMed ID: 25473779
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of In-Stent Restenosis: When the Stent Is No Longer There.
    Antuña P; Cuesta J; García-Guimaraes M; Bastante T; De Rueda C; Rivero F; Alfonso F
    JACC Cardiovasc Interv; 2020 Apr; 13(7):e53-e55. PubMed ID: 31883713
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Very Late Restenosis Following Bioresorbable Scaffold Implantation.
    Okuno T; Yahagi K; Horiuchi Y; Aoki J; Simonton CA; Rapoza R; Saito S; Kimura T; Tanabe K
    JACC Cardiovasc Interv; 2017 Sep; 10(18):e167-e169. PubMed ID: 28866033
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of coronary stent restenosis with drug-eluting bioabsorbable magnesium scaffolds.
    Alfonso F; Cuesta J; García-Guimaraes M; Bastante T; Maruri R; Rivero F
    Coron Artery Dis; 2017 Nov; 28(7):627-628. PubMed ID: 28644215
    [No Abstract]   [Full Text] [Related]  

  • 30. Recurrent Neoatherosclerosis After Bioresorbable Vascular Scaffold Treatment of In-Stent Restenosis.
    Bastante T; Rivero F; Benedicto A; Cuesta J; Alfonso F
    JACC Cardiovasc Interv; 2015 Aug; 8(9):1264-1265. PubMed ID: 26292592
    [No Abstract]   [Full Text] [Related]  

  • 31. Diagnostic Accuracy of Coronary CT Angiography for the Evaluation of Bioresorbable Vascular Scaffolds.
    Collet C; Chevalier B; Cequier A; Fajadet J; Dominici M; Helqvist S; Van Boven AJ; Dudek D; McClean D; Almeida M; Piek JJ; Tenekecioglu E; Bartorelli A; Windecker S; Serruys PW; Onuma Y
    JACC Cardiovasc Imaging; 2018 May; 11(5):722-732. PubMed ID: 28734923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neointimal proliferation is associated with clinical restenosis 2 years after fully bioresorbable vascular scaffold implantation.
    Indolfi C; Mongiardo A; Spaccarotella C; Caiazzo G; Torella D; De Rosa S
    Circ Cardiovasc Imaging; 2014 Jul; 7(4):755-7. PubMed ID: 25027457
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; Otaegui I; Masotti M; Zueco J; Veláquez M; Sanchís J; García-Touchard A; Lázaro-García R; Moreu J; Bethencourt A; Cuesta J; Rivero F; Cárdenas A; Gonzalo N; Jiménez-Quevedo P; Fernández C;
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1246-1255. PubMed ID: 27339840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioresorbable vascular scaffold implantation for recurrent in-stent restenosis: an option in case of multiple failures?
    Ielasi A; Saino A; Silvestro A; Personeni D; Tespili M
    EuroIntervention; 2014 Jul; 10(3):337. PubMed ID: 24647134
    [No Abstract]   [Full Text] [Related]  

  • 37. Unfavorable bioresorbable vascular scaffold resorption, a cause of restenosis?
    Ishida K; Giacchi G; Brugaletta S; García-Álvarez A; Sabaté M
    Cardiovasc Revasc Med; 2016 Dec; 17(8):571-573. PubMed ID: 27345841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial.
    Baan J; Claessen BE; Dijk KB; Vendrik J; van der Schaaf RJ; Meuwissen M; van Royen N; Gosselink ATM; van Wely MH; Dirkali A; Arkenbout EK; de Winter RJ; Koch KT; Sjauw KD; Beijk MA; Vis MM; Wykrzykowska JJ; Piek JJ; Tijssen JGP; Henriques JPS
    JACC Cardiovasc Interv; 2018 Feb; 11(3):275-283. PubMed ID: 29413242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.